Biotech Values

[ghmm]

Appreciate your and iwfal's points of Adaptive Trials. I can't add much to the discuss that hasn't been pointed out. I was curious on how the statistical analysis would be handled which you gave a couple possibilities for. If I recall correctly Emil had said about the possibility to enrich the trial by enrolling different types of patients (more likely to show benefit in a shorter period of time). Perhaps iwfal's skepticism is well founded and only those companies already good at running trials would navigate Adaptive Trials efficiently. The WSJ was more argue to the point of just how blinded are Placebo controlled trials along with patients gaming the entry criteria and some quitting when know not on study drug.